Quantitative monitoring of BCR/ABL1 mutants for surveillance of subclone-evolution, -expansion, and -depletion in chronic myeloid leukaemia

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 233-236

  Preuner, S ^a   Mitterbauer, G ^b   Mannhalter, C ^b   Herndlhofer, S ^c   Sperr, W R ^c,d   Valent, P ^c,d   Lion, T ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^b Institute of Medical Chemistry   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

CML; LD PCR; Mutation; TKD

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DASATINIB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; LIGASE; NILOTINIB;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLONE; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

CLONAL EVOLUTION; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; POINT MUTATION; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84655169099     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.08.015     Document Type: Article

References (22)

1. E. Jabbour, H. Kantarjian, and D. Jones Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate Leukemia 20 2006 1767 1773 (Pubitemid 44574988)
2. S. Soverini, S. Colarossi, and A. Gnani Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia Clin Cancer Res 12 2006 7374 7379 (Pubitemid 46095411)
3. F.E. Nicolini, S. Corm, and Q.H. Le Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP) Leukemia 20 2006 1061 1066 (Pubitemid 43797298)
4. S. Branford Chronic myeloid leukemia: molecular monitoring in clinical practice Hematol Am Soc Hematol Edu Program 2007 376 383
5. J.F. Apperley Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia Lancet Oncol 8 2007 1018 1029 (Pubitemid 47629897)
6. S. Branford, J.V. Melo, and T.P. Hughes Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 114 2009 5426 5435
7. H. de Lavallade, J.F. Apperley, and J.S. Khorashad Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis J Clin Oncol 26 2008 3358 3363
8. J.S. Khorashad, H. de Lavallade, and J.F. Apperley Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression J Clin Oncol 26 2008 4806 4813
9. R.D. Press, S.G. Willis, J. Laudadio, M.J. Mauro, and M.W. Deininger Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib Blood 114 2009 2598 2605
10. P. Sharma, S. Mohanty, V. Kochupillai, and L. Kumar Mutations in ABL kinase domain are associated with inferior progression-free survival Leuk Lymphoma 51 2010 1072 1078
11. S.G. Willis, T. Lange, and S. Demehri High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy Blood 106 2005 2128 2137 (Pubitemid 41291730)
12. E. Jabbour, S. Branford, and G. Saglio Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia Cancer 117 2011 1800 1811
13. J.S. Khorashad, M. Anand, and D. Marin The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib Leukemia 20 2006 658 663
14. D.W. Sherbenou, O. Hantschel, and I. Kaupe BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib Blood 116 2010 3278 3285
15. S. Branford, and T.P. Hughes Practical considerations for monitoring patients with chronic myeloid leukemia Semin Hematol 47 2010 327 334
16. J.S. Khorashad, D. Milojkovic, and P. Mehta In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib Blood 111 2008 2378 2381 (Pubitemid 351451447)
17. S. Preuner, D. Denk, F. Frommlet, M. Nesslboeck, and T. Lion Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR) Leukemia 22 2008 1956 1961
18. S. Branford, and T. Hughes Detection of BCR-ABL mutations and resistance to imatinib mesylate Methods Mol Med 125 2006 93 106
19. S. Soverini, A. Gnani, and S. Colarossi Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors Blood 114 2009 2168 2171
20. P. Valent Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept Curr Cancer Drug Targets 11 2010 56 71
21. M. Greaves Cancer stem cells: back to Darwin? Semin Cancer Biol 20 2010 65 70
22. F. Notta, C.G. Mullighan, and J.C. Wang Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells Nature 469 2011 362 367